Verona Pharma
Biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases.
Launch date
Employees
Market cap
€2.2b
Enterprise valuation
€2.2b (Public information from Sep 2024)
Share price
£0.5489 VRP.L
Company register number 05375156
Cardiff Wales (HQ)
Financials
Estimates*
| GBP | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | 30.0m | <1m | - | 5.4m | 64.9m | 297m |
| % growth | - | - | (99 %) | - | - | 1105 % | 358 % |
| EBITDA | (52.0m) | (60.3m) | (64.3m) | - | - | - | - |
| % EBITDA margin | - | (201 %) | (16929 %) | - | - | - | - |
| Profit | (46.0m) | (42.0m) | (57.0m) | (43.0m) | (142m) | (94.8m) | 88.7m |
| % profit margin | - | (140 %) | (15000 %) | - | (2647 %) | (146 %) | 30 % |
| EV / revenue | - | 7.2x | 4155.3x | - | 315.6x | 26.2x | 5.7x |
| EV / EBITDA | -3.1x | -3.6x | -24.5x | - | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | IPO | |
$11.5m | Post IPO Equity | ||
£44.7m | Post IPO Equity | ||
* | N/A | $77.1m Valuation: $163m -17.9x EV/LTM EBITDA | IPO |
$200m | Post IPO Equity | ||
$30.0m | Post IPO Debt | ||
* | N/A | $130m | Post IPO Equity |
* | $150m | Post IPO Debt | |
* | $400m | Post IPO Debt | |
* | $250m | Post IPO Equity | |
| Total Funding | - | ||
Recent News about Verona Pharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.